This tiny biotech has a long history of failure, but it also has a flu vaccine that is likely to be approved by the FDA.
News & Analysis: Novavax
Novavax's RSV vaccine may not be dead after all.
Novavax's proposed reverse split has investors on edge.
Investors' optimism about the prospects for the biotech's experimental vaccines appears to be increasing.
Novavax's latest clinical failure may prove to difficult to overcome.
Its RSV vaccine fails to hit the mark, again.
Progress with two vaccines pushed the stock up last year.
Novavax's experimental flu vaccine hits the mark in a highly anticipated midstage trial.
Investors anticipating two important clinical trial readouts gave the volatile biotech stock some lift.
The clinical-stage biotech stock appeared to get a bump from three separate reports.
A Wall Street analyst turned bullish -- and the market responded in kind. But investors may want to consider the binary nature of this biopharma stock.